PlainRecalls
FDA Drug Low Class III Terminated

Buprenorphine and Naloxone Sublingual Tablets, 2 mg/0.5 mg 30 tablets per bottle, Rx only, Distributed by: Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 0093-5720-56

Reported: July 26, 2017 Initiated: June 29, 2017 #D-0983-2017

Product Description

Buprenorphine and Naloxone Sublingual Tablets, 2 mg/0.5 mg 30 tablets per bottle, Rx only, Distributed by: Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 0093-5720-56

Reason for Recall

Failed Impurities/Degradation Specifications: out of specification test results for related compounds largest unknown impurity.

Details

Recalling Firm
Teva Pharmaceuticals USA
Units Affected
25264 bottles
Distribution
Nationwide in the USA
Location
North Wales, PA

Frequently Asked Questions

What product was recalled?
Buprenorphine and Naloxone Sublingual Tablets, 2 mg/0.5 mg 30 tablets per bottle, Rx only, Distributed by: Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 0093-5720-56. Recalled by Teva Pharmaceuticals USA. Units affected: 25264 bottles.
Why was this product recalled?
Failed Impurities/Degradation Specifications: out of specification test results for related compounds largest unknown impurity.
Which agency issued this recall?
This recall was issued by the FDA Drug on July 26, 2017. Severity: Low. Recall number: D-0983-2017.